GlassScriptPhysician profile
Obed Perez Gonzalez
NPI 1255420444
$1,461.90
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $83.34 · 2021: $279 · 2022: $340 · 2023: $429 · 2024: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479 · Education: $84.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.25 |
| Education | $84.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $575.60 | 2019-2023 | Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $189.01 | 2019-2023 | |
| Lilly USA, LLC | $186.12 | 2023-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.75 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $92.07 | 2019-2022 | |
| Medtronic, INC. | $84.86 | 2023 | Minimed 780g |
| Merck Sharp & Dohme LLC | $66.32 | 2019-2021 | |
| Abbvie INC. | $49.87 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $39.61 | 2019 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $38.69 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obed Perez Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.